Outspoken doctor’s pancreas study prompted FDA’s new diabetes-drug probe

Carly Helfand Inconclusive data, confounding variables, as-yet-unreplicated results–they're all reasons critics have dismissed a link between incretin mimetics, a class of ...

Idenix Pharmaceuticals Announces Initiation of Phase II All-Oral Combination Study of Samatasvir and Simeprevir

barbara.lempert Idenix Pharmaceuticals Announces Initiation of Phase II All-Oral Combination Study of Samatasvir (IDX719) and Simeprevir  (TMC435) for the Treatment of Hepatitis C ...

Medicare Spending Variations Mostly Due To Health Differences, Study Concludes

barbara.lempert By Jordan Rau KHN Staff Writer The idea that uneven Medicare health care spending around the country is due to wasteful practices and overtreatment—a concept that ...

Targacept Announces Initiation of Phase 2b Study of TC-5214 in Overactive Bladder

barbara.lempert Winston-Salem, NC—May 29, 2013—Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics ™, today announced ...

Study: Physicians Insufficiently Informed of Drug Side Effects

barbara.lempert An international study involving 255 physicians practising in Vancouver, Montreal, Sacramento and Toulouse found that physicians are not given enough information about ...

Novo spearheads $175M financing to back Ophthotech’s PhIII AMD study

John Carroll New York-based Ophthotech has rounded up a whopping $ 175 million in financing to cover a pivotal late-stage study of its lead drug for wet AMD. The biotech signed a deal ...

Drugmakers to reap $115B in sales as Obamacare rolls on, study finds

Tracy Staton Big Pharma will soon see the payoff from Obamacare. Citing a new GlobalData study, Forbes says the industry stands to reap an additional $ 35 billion in profits as the ...

Novartis apologizes over Diovan study as probe shows employee involvement in trials

Eric Palmer Novartis' blood pressure Diovan is on the wane as its expects generics next quarter to begin eating at its blockbuster status. But even as it comes under attack by generics, ...

How Much?! AbbVie Raises Niaspan Price Despite Study Failures

esilverman Over the past two years, two studies showed the Niaspan cholesterol drug did not benefit patients. Yet AbbVie has managed to maintain revenue generated by the pill using ...

First patient dosed in the Phase I/II study of Umecrine Mood’s candidate drug for premenstrual dysphoric disorder

barbara.lempert STOCKHOLM – May 23, 2013. Umecrine Mood AB announced today that dosing has been initiated in a randomized Phase I/II study of UC1010 for the treatment of patients ...

Sanofi highlights positive PhIII study for myelofibrosis contender

Ryan McBride The pivotal study for SAR302503 nailed the primary endpoint for the proportion of patients with a greater than 35% reduction in the volume of their spleens, which become ...

Z-Pak’s fatal risks don’t apply to the average patient, new study finds

Tracy Staton The popular Z-Pak antibiotic, linked to heart-rhythm problems in March, may not be risky for the average patient, a new study suggests. The FDA maintains that patients ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS